SCHEMBL1767840

SCHEMBL1767840

O=Cc1nc2ccccc2c(Br)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.47
MAOB P27338 1/20 0.47
ERN1 O75460 1/20 0.38
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
CHRM2 P08172 1/20 0.34
ADRA2A P08913 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CHRM1 P11229 1/20 0.34
HPGD P15428 1/20 0.34
NQO2 P16083 1/20 0.34
DRD1 P21728 1/20 0.34
ACHE P22303 1/20 0.34
SLC6A2 P23975 1/20 0.34
CASP1 P29466 1/20 0.34
ADRA1A P35348 1/20 0.34
OPRM1 P35372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23780919 0.76 ERN1 (0.45) MAOAMAOBERN1ALDH1A1MAPT
SCHEMBL25213590 0.76 MAOA (0.56) MAOAMAOBALDH1A1MAPTSMN1; SMN2
SCHEMBL3907383 0.74 GPR3 (0.48) MAOAMAOBERN1ALDH1A1MAPT
SCHEMBL31413138 0.73 MAOA (0.52) MAOAMAOBALDH1A1MAPTSMN1; SMN2
SCHEMBL28953244 0.72 MAOA (0.52) MAOAMAOBERN1ALDH1A1MAPT
SCHEMBL13096599 0.71 MAPT (0.45) MAOAMAOBALDH1A1MAPTSMN1; SMN2
SCHEMBL2512737 0.70 KDM4E (0.56) MAOAMAOBALDH1A1MAPTSMN1; SMN2
SCHEMBL20551851 0.70 MAPT (0.42) ERN1ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL3706723 0.70 TDP1 (0.58) MAOAMAOBALDH1A1MAPTSMN1; SMN2
SCHEMBL30366834 0.70 TDP1 (0.58) MAOAMAOBALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822485-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-09-02 US disclosed
US-20130018064-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2013-01-17 US disclosed
EP-2504330-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063272-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018064-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP MAOA 167/4885MAOB 83/4885ERN1 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.